柏林，2009年12月3日（美国商业资讯） - 在KMIS会议（Klinisch-Mikrobiologisch-Infektiologisches研讨会）上，2009年12月3日至5日在柏林，布鲁克·道尔顿学（Bruker Daltonics）宣布与Synlab（www.synlab.de）达成框架协议关于基于MALDI-TOF质谱法的分子微生物鉴定。Synlab是欧洲私人诊断实验室协会，Bruker Daltonics是基于质谱的微生物鉴定解决方案的全球领先提供商。Synlab目前在德国和其他欧洲国家拥有70多个诊断实验室。
Synlab和Bruker已缔结了一项长期合作协议，以使Synlab协会的实验室专门为MALDI Biotyper快速可靠的分子微生物鉴定系统。这MALDI Biotyper目前已经在Synlab的Trier，Weiden和Dachau的Synlab临床微生物学中心进行常规使用。此外，Bruker和Synlab打算进一步扩大和完善MALDI Biotyper参考文献使用良好的Synlab实验室每日微生物学常规工作中定义明确的临床分离株。
这MALDI Biotyper是integrated into the Synlab laboratories' microbiology workflow, combining fast molecular identification with conventional antibiotic susceptibility testing (AST). TheMALDI Biotyper将标识结果报告给现有的实验室信息系统（LIS）。与Lis MCS集成（http://www.mcs-ag.com), Medat (http://www.medat.de）和Vision4Health（http://www.vision4health.com）已经建立了Synlab，而与其他LIS提供商也可以集成。
Trier Synlab的微生物学技术负责人Ulrich Knipp博士评论说：“在评估之后MALDI Biotyper在Synlab组中非常彻底，我们坚信Bruker Daltonics是基于质谱的微生物识别最可靠的合作伙伴，并且提供出色的微生物服务和支持。bob电竞官方网站Bruker Daltonics已在临床微生物学市场中充分建立MALDI Biotyper满足我们对可靠性和鲁棒性的要求。这MALDI Biotyper代表了一个明确的里程碑，证实了我们的高质量分子微生物学诊断。”
Bruker Daltonics微生物学主任Guido Mix博士补充说：“我们很高兴我们MALDI Biotyper满足了Synlab等领先的临床实验室的高度要求。我们与Synlab的框架合同验证了我们的努力，通过专门的微生物学家，完全开发的技术人员网络以及专门的IT专家将其集成到各种实验室信息系统（LIS）中，为客户提供全面bob电竞官方网站的服务和应用支持。”
关于布鲁克MALDI Biotyper
布鲁克的奉献精神MALDI Biotyper解决方案 （http://www.bdal.com）实现细菌，酵母和真菌等微生物的分子鉴定以及分类学分类或消除微生物。使用高通量MALDI-TOF质谱法蛋白质组学指纹识别微生物的分类和鉴定是可靠而快速实现的。应用包括临床常规微生物识别，环境和药物分析，分类学研究，食品和消费者产品安全和质量控制以及海洋微生物学。Bruker的强大MALDI BIOTYPER方法需要最少的样品准备工作，并且每个样品的消耗量低。这MALDI Biotyperis available in a research-use-only version, as well as in an IVD-CE version according to EU directive EC/98/79 in certain European countries.
关于布鲁克公司（纳斯达克：BRKR）
Bruker is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis. For more information://www.energie2point0.com
警告声明
Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, realization of anticipated benefits from economic stimulus programs, intellectual property rights, litigation, and exposure to foreign currency fluctuations and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our recent Proxy Statements on Schedule 14A, our annual report on Form 10-K for the year ended December 31, 2008, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law. >
照片/多媒体画廊可用：http://www.businesswire.com
资料来源：布鲁克·道尔顿学
Karin Hoffmann， +49-421-2205-2041
MALDI BIOTYPER营销，Bruker Daltonics
kho@bdal.de